| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in operating activities | -18,836,673 | -8,781,048 |
| Proceeds from issuance of common shares pursuant to atm offering, net of issuance costs | 708,468 | - |
| Proceeds from issuance of pre-funded warrants from july 22, 2025 registered direct offering, net of issuance costs | 697,658 | - |
| Proceeds from issuance of common shares, pre-funded warrants, and accompanying warrants from july 26, 2024 pipe, net of issuance costs-July222025Exercise Of Discounted Warrants And Pipe Offering | 8,391,027 | - |
| Proceeds from issuance of common shares, pre-funded warrants, and accompanying warrants from july 26, 2024 pipe, net of issuance costs-July282025Exercise Of Discounted Warrants And Pipe Offering | 11,144,468 | - |
| Proceeds from exercise of pre-funded warrants | 3,050 | - |
| Net cash provided by financing activities | 20,944,671 | - |
| Net increase in cash | 2,107,998 | -8,781,048 |
| Cash and cash equivalents at beginning of period | 13,291,167 | - |
| Cash and cash equivalents at end of period | 15,399,165 | - |
ProMIS Neurosciences Inc. (PMN)
ProMIS Neurosciences Inc. (PMN)